Drug profile · INN
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran)
COMIRNATY (NOTE 2) (MONOVALENT, ORIGINAL) INITIAL APPROVAL
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran) (COMIRNATY (NOTE 2) (MONOVALENT, ORIGINAL) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
Drug details — coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran)
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran) (COMIRNATY (NOTE 2) (MONOVALENT, ORIGINAL) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Frequently asked questions
What is coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran)?
coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran) (COMIRNATY (NOTE 2) (MONOVALENT, ORIGINAL) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran)?
COMIRNATY (NOTE 2) (MONOVALENT, ORIGINAL) INITIAL APPROVAL is a marketed brand name for coronavirus modified uridine rna vaccine (sars-cov-2) (active ingredient: tozinameran). Check FDA Drugs@FDA for the current US label holder and prescribing information.